Indications and uses
Symptomatic treatment of skin tags
Symptomatic treatment of skin tags
use brush to apply 3 times daily to affected area skin tags will dry and flake away over 3-8 weeks skin test for tolerability if irritation occurs, discontinue use
store at 20-25 degrees C (68-77 degrees F)
Thuja Occidentalis 6X (HPUS)
Symptomatic treatment of skin tags
For external use only
ask a health care professional before use.
store at 20-25 degrees C (68-77 degrees F)
Cedar Leaf Oil, Melaleuca Alternifolia Leaf Oil, Ricinus Communis Seed Oil.
For Chemical Emergency, Spill, Fire or Accident
Call Chemtrec 24 hours- N. Amer.: 800-424-9300
Outside USA: 703-527-3887 (collect)
| Resource | Code type | Value | Equivalent identifiers | Source image |
|---|---|---|---|---|
| Barcode | EAN-13 | 0893621002344 | GTIN-13: 0893621002344 EAN-13: 0893621002344 GTIN-12: 893621002344 UPC-A: 893621002344 GTIN storage (14 digits): 00893621002344 | TagAway.jpg |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 65121-711-15 | Tag Away | 15 mL in 1 BOTTLE, GLASS | LIQUID | 15 | 13 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| THUJA OCCIDENTALIS LEAFY TWIG | ACTIVE INGREDIENT | 1NT28V9397 | 11 | |
| THUJA OCCIDENTALIS LEAFY TWIG | ACTIVE MOIETY | 1NT28V9397 | 11 | |
| CASTOR OIL | INACTIVE INGREDIENT | D5340Y2I9G | 11 | |
| CEDAR LEAF OIL | INACTIVE INGREDIENT | BJ169U4NLG | 11 | |
| TEA TREE OIL | INACTIVE INGREDIENT | VIF565UC2G | 11 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 65121-711 | 65121-711-15 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CEDAR LEAF OIL | BJ169U4NLG | IACT |
| TEA TREE OIL | VIF565UC2G | IACT |
| CASTOR OIL | D5340Y2I9G | IACT |
| THUJA OCCIDENTALIS LEAFY TWIG | 1NT28V9397 | ACTIB |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| CASTOR OIL | CASTOR OIL | D5340Y2I9G | TABLET, EXTENDED RELEASE / ORAL | 23.27 mg | ||
| CASTOR OIL | CASTOR OIL | D5340Y2I9G | TABLET, COATED / ORAL | 0.9 mg | ||
| CASTOR OIL | CASTOR OIL | D5340Y2I9G | GRANULE, FOR SUSPENSION / ORAL | 128 mg | ||
| CASTOR OIL | CASTOR OIL | D5340Y2I9G | TABLET / SUBLINGUAL | 1.6 mg | ||
| CASTOR OIL | CASTOR OIL | D5340Y2I9G | TABLET / ORAL | 17 mg | ||
| CASTOR OIL | CASTOR OIL | D5340Y2I9G | CAPSULE, EXTENDED RELEASE / ORAL | 47 mg | ||
| CASTOR OIL | CASTOR OIL | D5340Y2I9G | EMULSION / OPHTHALMIC | 32 mg | ||
| CASTOR OIL | CASTOR OIL | D5340Y2I9G | SPRAY / NASAL | NA | ||
| CASTOR OIL | CASTOR OIL | D5340Y2I9G | OINTMENT / TOPICAL | 14.9 %w/w | ||
| CASTOR OIL | CASTOR OIL | D5340Y2I9G | CAPSULE / ORAL | 1.04 mg | ||
| CASTOR OIL | CASTOR OIL | D5340Y2I9G | GEL / NASAL | 429 mg | ||
| CASTOR OIL | CASTOR OIL | D5340Y2I9G | INJECTION, SOLUTION / INTRAMUSCULAR | 525 mg | ||
| CASTOR OIL | CASTOR OIL | D5340Y2I9G | SOLUTION / TOPICAL | 1.38 %w/w | ||
| CASTOR OIL | CASTOR OIL | D5340Y2I9G | TABLET, DELAYED RELEASE / ORAL | 0.01 mg | ||
| CASTOR OIL | CASTOR OIL | D5340Y2I9G | TABLET, FILM COATED / ORAL | 15.29 mg | ||
| CASTOR OIL | CASTOR OIL | D5340Y2I9G | INJECTION / INTRAMUSCULAR | 885 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 482e2384-ef7a-01c7-e054-00144ff88e88 | 252e94ff-7b44-4ee2-9684-f7b4122cdc88 | 2017-02-10 | Warnings | 482e2384-ef7a-01c7-e054-00144ff88e88 252e94ff-7b44-4ee2-9684-f7b4122cdc88 |
Adverse event summaries are temporarily unavailable. Other product information remains available.